

Amendments to the Specification

Please delete the paragraphs spanning page 5, lines 36 to page 6, line 10 and substitute the following replacement section:

Figure 1 illustrates the insertion of the DNA sequence for *E. coli* β -glucuronidase (*E. coli* β Glu for: SEQ ID NO:1 and *E. coli* β Glu backr: SEQ ID NO: 2) into the vector p bluescript II KS (KS) to produce vector KS/A.c.- β -Gluc. The sequences of the primers used to amplify the β -glucuronidase gene are also shown.

Figure 2 shows the sequences of the primers used to amplify the antibody variable domain VH and the CH1 constant domain from the cDNA construct HC-hum- β -glucuronidase (Fab HC for: SEQ ID NO: 3 and Fab HC back: SEQ ID NO: 4). This Figure also shows the cloning of the VH/CH1 region into vector KS by cleavage of the HC-hum- β -glucuronidase using XbaI and EcoRI restriction sites to produce vector KS/Fab HC.

Please delete the paragraph on page 6, lines 20 - 23 and substitute the following replacement paragraph:

Figure 5a-5e 5b – 5i shows the nucleotide (SEQ ID NO: 5) and corresponding amino acid sequences (SEQ ID NO: 7) for the VH, CH1 and *E. coli* β -glucuronidase coding sequences inserted into the vector pTrc99/dicistr. Fab/E.c. β -Gluc.

Please delete the paragraph on page 14, lines 9-12 and substitute the following replacement paragraph:

The DNA sequence encoding *E. coli* β -glucuronidase was amplified by PCR from the *E. coli* strain RR1 using the primers E.c. β Gluc. For (AAG CTT TCA TTG TTT GCC TCC CTG CTG CGG SEQ ID NO: 1) and E.c. β Gluc. back (TCT AGA CCA TGG TAC GTC CTG TAC AAA CCC CA SEQ ID NO: 2), and cloned into the vector P bluescript II KS (Stratagene, La Jolla, Calif.) by way of the Xba I and Hind III sites (Fig. 1).

Please delete the paragraph on page 14, lines 15-31 and substitute the following replacement paragraph:

The antibody variable domain VH and the constant domain CH1 were amplified by PCR from an HC-Human- β -glucuronidase cDNA construct, using the primers Fab HC forward (GAA TTC CAT GGA AAC AGA ACC AGA ACC GAG CTC AAC TCT SEQ ID NO: 3) and Fab HC back (TCT AGA TAA CGA GGG CAA AAA ATG GAG GTC CAA CTG CAG SEQ ID NO: 4), and cloned into vector p bluescript II KS by way of the Xba I and Eco RI sites (Fig. 2). See Bosslet et al., Br. J. Cancer, 65, 234 – 238, 1992 and Güssow & Seeman, *Methods in Enzymology*, 203:99-121 (1991). Bosslet describes the construction of the vector comprising a cDNA sequence encoding humanized VH (derived from the VH gene of Mab BW431) and CH1, fused to the gene for human β -glucuronidase that was used in this step. Briefly, the fusion gene comprises the human IgG promoter region and signal peptide exon, the humanized version of the VH gene of Mab BW431 (described in Güssow, *supra*), and the CH1 exon of human IgG3.